[
    [
        {
            "time": "",
            "original_text": "医药生物行业周报：CXO、医疗服务、生物制品等板块预计Q1高增长",
            "features": {
                "keywords": [
                    "医药生物",
                    "CXO",
                    "医疗服务",
                    "生物制品",
                    "Q1高增长"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物制品",
                    "医疗服务"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物行业周报：CXO、医疗服务、生物制品等板块预计Q1高增长",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "首创证券---医药生物行业简评报告：从PEG的角度看，部分优质医药资产估值已具有吸引力【行业研究】",
            "features": {
                "keywords": [
                    "首创证券",
                    "医药生物",
                    "PEG",
                    "优质医药资产",
                    "估值吸引力"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "首创证券---医药生物行业简评报告：从PEG的角度看，部分优质医药资产估值已具有吸引力【行业研究】",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        }
    ]
]